|
Moderna Inc (NASDAQ: MRNA) |
|
Moderna Inc
MRNA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Moderna Inc 's sales fell
by -65.64 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1391
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.69 %
Moderna Inc faced net loss in contrast to the net income a year ago in IV. Quarter 2024
• More on MRNA's Growth
|
|
Moderna Inc realized a net loss in trailing twelve months.
Moderna Inc realized cash reduction of $ -2.6 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.12.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.65.
• More on MRNA's Valuation
|
|
|
|
|
Moderna Inc realized net loss in trailing twelve months.
Moderna Inc realized cash outflow of $ -2.6per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.12.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.65.
Moderna Inc Price to Book Ratio is at 1.22 lower than Industry Avg. of 1417.61. and higher than S&P 500 Avg. of 0.01
• More on MRNA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com